Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection

(2022) Theodoros Androutsakos et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases

(2022) Amin Hasanvand   INFLAMMOPHARMACOLOGY

Treatments for NAFLD: State of Art

(2021) Alessandro Mantovani et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Peri-renal adipose inflammation contributes to renal dysfunction in a non-obese prediabetic rat model: Role of anti-diabetic drugs

(2021) Safaa H. Hammoud et al.   BIOCHEMICAL PHARMACOLOGY

Modulatory Effect of Intermittent Fasting on Adipose Tissue Inflammation: Amelioration of Cardiovascular Dysfunction in Early Metabolic Impairment

(2021) Haneen S. Dwaib et al.   Frontiers in Pharmacology

Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

(2021) Won Euh et al.   Frontiers in Endocrinology

Sex Differences in Cardiovascular Impact of Early Metabolic Impairment: Interplay between Dysbiosis and Adipose Inflammation

(2021) Haneen S Dwaib et al.   MOLECULAR PHARMACOLOGY

Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review

(2020) Anton Gillessen et al.   ADVANCES IN THERAPY

Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease

(2020) Rim Rafeh et al.   CLINICAL SCIENCE

Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver

(2020) Mohammed Kh. ElMahdy et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

(2020) Daniel Q. Huang et al.   Nature Reviews Gastroenterology & Hepatology

Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases

(2020) Ibrahim AlZaim et al.   Frontiers in Cardiovascular Medicine

Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of non-obese prediabetic metabolic challenge: Potential role of anti-diabetic drugs

(2019) Mohammed A.W. Elkhatib et al.   Translational Research

Dietary fat, cholesterol, and cholic acid affect the histopathologic severity of nonalcoholic steatohepatitis in Sprague-Dawley rats

(2019) Ayumi Fukuda et al.   PATHOLOGY RESEARCH AND PRACTICE

Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE−/− mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation

(2019) Dan Feng et al.   Nutrition & Metabolism

Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

(2018) Vignan Manne et al.   Clinics in Liver Disease

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects

(2018) Abdullah Kaplan et al.   HEART FAILURE REVIEWS

Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”

(2018) Yan-Lan Fang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2018) Masanori Shimizu et al.   DIABETES OBESITY & METABOLISM

Mechanisms of hepatic stellate cell activation

(2017) Takuma Tsuchida et al.   Nature Reviews Gastroenterology & Hepatology

Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice

(2016) Jelske N. van der Veen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum

(2016) Timothy Hardy et al.   Annual Review of Pathology-Mechanisms of Disease

Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?

(2016) Bin Gao et al.   GASTROENTEROLOGY

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)

(2016) Elena Buzzetti et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Oxidative Stress Related Diseases in Newborns

(2016) Yasemin Ozsurekci et al.   Oxidative Medicine and Cellular Longevity

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats

(2015) Simona Clichici et al.   JOURNAL OF MEDICINAL FOOD

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

(2015) Shirong Qiang et al.   Diabetology & Metabolic Syndrome

Oxidative stress: a concept in redox biology and medicine

(2015) Helmut Sies   Redox Biology

Nonalcoholic fatty liver disease

(2015) Elizabeth M. Brunt et al.   Nature Reviews Disease Primers

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

(2014) D Shyangdan et al.   HEALTH TECHNOLOGY ASSESSMENT

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

(2014) Atsuo Tahara et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

α-lipoic acid reduces fatty acid esterification and lipogenesis in adipocytes from overweight/obese subjects

(2014) Marta Fernández-Galilea et al.   Obesity

Pleiotropic Roles of Bile Acids in Metabolism

(2013) Thomas Q. de Aguiar Vallim et al.   Cell Metabolism

Betaine Protects Against High-Fat-Diet-Induced Liver Injury by Inhibition of High-Mobility Group Box 1 and Toll-Like Receptor 4 Expression in Rats

(2013) Wei Zhang et al.   DIGESTIVE DISEASES AND SCIENCES

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Therapeutic Effect of Metformin and Vitamin E Versus Prescriptive Diet in Obese Adolescents with Fatty Liver

(2013) Akcam et al.   INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH

Association between metabolic syndrome and the development of non-alcoholic fatty liver disease

(2013) YI WANG et al.   Experimental and Therapeutic Medicine

An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training

(2012) Isabelle Côté et al.   EUROPEAN JOURNAL OF NUTRITION

Oxidative Stress and Antioxidant Defense

(2012) Esra Birben et al.   World Allergy Organization Journal

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The role of oxidative stress in non-alcoholic steatohepatitis

(2011) G.H. Koek et al.   CLINICA CHIMICA ACTA

A High-Cholesterol Diet Exacerbates Liver Fibrosis in Mice via Accumulation of Free Cholesterol in Hepatic Stellate Cells

(2011) Toshiaki Teratani et al.   GASTROENTEROLOGY

AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan

(2011) Antero Salminen et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks

(2011) S. Alers et al.   MOLECULAR AND CELLULAR BIOLOGY

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

(2010) M. O. Rakoski et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Insulin Resistance in Nonalcoholic Fatty Liver Disease

(2010) E. Bugianesi et al.   CURRENT PHARMACEUTICAL DESIGN

Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease

(2010) R. N. Hardwick et al.   DRUG METABOLISM AND DISPOSITION

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding Protein

(2009) Ling He et al.   CELL

Characterization of High-Fat, Diet-Induced, Non-alcoholic Steatohepatitis with Fibrosis in Rats

(2009) Zheng-Jie Xu et al.   DIGESTIVE DISEASES AND SCIENCES

Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage

(2009) E. Shaker et al.   FOOD AND CHEMICAL TOXICOLOGY

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

(2008) R. LOOMBA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Gene expression in human NAFLD

(2008) Dario Greco et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Cellular and Molecular Mechanisms of Liver Injury

(2008) Harmeet Malhi et al.   GASTROENTEROLOGY

Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis

(2008) Kristiaan Wouters et al.   HEPATOLOGY

Balancing cholesterol synthesis and absorption in the gastrointestinal tract

(2008) David E. Cohen   Journal of Clinical Lipidology